Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
71 hedge funds and large institutions have $59.1M invested in Antares Pharma, Inc. in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 29 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
3% more capital invested
Capital invested by funds: $57.2M → $59.1M (+$1.97M)
14% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 21
14% less funds holding
Funds holding: 83 → 71 (-12)
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $15K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.23M |
| 2 |
PLP
Pleasant Lake Partners
Rincon,
Puerto Rico
|
+$968K |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$733K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$558K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$498K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$3.86M |
| 2 |
Morgan Stanley
New York
|
-$2.47M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.92M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.43M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.35M |
ATRS Hedge Fund Activity: Q2 2016 in Review
71 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2016, worth a combined $59.1M — up 3.5% from $57.2M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ATRS and 17 opened new positions — a net loss of 12 holders — while 21 trimmed existing stakes and 18 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.23M. The largest seller was BlackRock Fund Advisors, cutting an estimated $3.86M.
- 71 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2016, down from 83 in Q1 2016.
- Funds reported $59.1M of Antares Pharma, Inc. stock for Q2 2016, up 3.5% quarter-over-quarter.
- 17 funds opened new Antares Pharma, Inc. positions in Q2 2016 and 29 closed out, a net change of -12 holders.
- The largest Antares Pharma, Inc. buyer in Q2 2016 was Millennium Management, an estimated $1.23M added.
- The largest Antares Pharma, Inc. seller in Q2 2016 was BlackRock Fund Advisors, an estimated $3.86M sold.
Based on aggregated 13F filings for Q2 2016.